

**RESPONSE UNDER 37 CFR 1.116
EXPEDITED PROCEDURE
EXAMINING GROUP NO. 1642**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: **Vinson, Puddefoot, and Barker**

Title: **Therapeutic Uses Of Monoclonal Antibodies To The Angiotensin-II Type 1 Receptor**

Serial No.: **10/525,277**

Group Art Unit: **1642**

Filed: **February 22, 2005**

Examiner: **Lei Yao**

Confirmation No.: **6075**

Filed by EFS Web on: **14 December 2010**

Mail Stop AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

RESPONSE UNDER 37 C.F.R. §1.116

In response to the final Office Action dated November 9, 2010 in regard to the above-identified patent application, Applicants respectfully request that the application be amended as follows.

Amendment of the Specification begins at page 2.

Amendment of the Claims begins at page 3.

Remarks begin at page 5.